XML 100 R82.htm IDEA: XBRL DOCUMENT v3.25.1
Commitments and Contingencies - Additional Information (Detail) - USD ($)
 1 Months Ended 12 Months Ended
Aug. 26, 2024
Oct. 30, 2023
Feb. 28, 2023
Dec. 31, 2024
Dec. 31, 2023
Commitments And Contingencies Disclosure [Line Items]          
CVR derivative liability         $ 4,722,000
Purchase of property and equipment       $ 2,315,000 8,517,000
Property and Equipment          
Commitments And Contingencies Disclosure [Line Items]          
Purchase of property and equipment       1,400,000  
Research and Development          
Commitments And Contingencies Disclosure [Line Items]          
Committed to allocate       $ 20,300,000  
Contingent Value Rights Agreement          
Commitments And Contingencies Disclosure [Line Items]          
Percentage of excess cash on dispositions net       100.00%  
Excess amount retained from net proceeds related to disposition of assets       $ 1,000,000  
Percentage of excess preapproved costs       100.00%  
Distribution to CVR holders from asset sale proceeds     $ 200,000    
Long-term CVR derivative liability     $ 4,500,000    
CVR derivative liability       $ 5,000,000 $ 4,700,000
Contributions closing payable amount   $ 1,100,000      
Distributions to holders $ 12,600,000        
Distributions to holders per CVR $ 0.4        
Remaining outstanding balance       $ 0  
Vertex Asset Purchase Agreement | Contingent Value Rights Agreement          
Commitments And Contingencies Disclosure [Line Items]          
Percentage of amount received on agreement       100.00%  
F351 | Gyre Pharmaceuticals          
Commitments And Contingencies Disclosure [Line Items]          
Payments for exchange of intellectual property rights       $ 0  
F351 | Gyre Pharmaceuticals | Submission of the New Drug Application          
Commitments And Contingencies Disclosure [Line Items]          
Obligation to pay in exchange for the intellectual property rights       4,600,000  
F351 | Gyre Pharmaceuticals | NDA Passes the NMPA's Review and Inspection          
Commitments And Contingencies Disclosure [Line Items]          
Obligation to pay in exchange for the intellectual property rights       1,200,000  
F351 | Gyre Pharmaceuticals | NMPA's Approval of the NDA          
Commitments And Contingencies Disclosure [Line Items]          
Obligation to pay in exchange for the intellectual property rights       $ 6,900,000